Explore

Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements

Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements

Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements
Trendline Trendline
CDMO Sector Faces Transformation Amidst U.S. Economic Policies and Technological Advances

CDMO Sector Faces Transformation Amidst U.S. Economic Policies and Technological Advances

CDMO Sector Faces Transformation Amidst U.S. Economic Policies and Technological Advances
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development

Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development

Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development
Trendline Trendline
Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations
Trendline Trendline
Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development

Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development

Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development
Trendline Trendline
Achieve Life Sciences Completes Technology Transfer to Adare Pharma Solutions

Achieve Life Sciences Completes Technology Transfer to Adare Pharma Solutions

Achieve Life Sciences Completes Technology Transfer to Adare Pharma Solutions
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs
Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
AbbVie Enters Pain Management Market with $715 Million Deal with Haisco

AbbVie Enters Pain Management Market with $715 Million Deal with Haisco

AbbVie Enters Pain Management Market with $715 Million Deal with Haisco